Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 4: 631 - 639

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230517.002

Meta-analysises

Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis

  • Wu SUN ,
  • Yuwei ZHAO ,
  • Liang LIAO ,
  • Zhonghui ZHAO ,
  • Shiqi CHEN ,
  • Xiaoling YAN ,
  • Xueyao WANG ,
  • Guojun CHAO ,
  • Jian ZHOU
Expand
  • 1 Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
    2 Beijing University of Chinese Medicine, Beijing 100029, China
    3 Department of Retina, Eye Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100040, China
    4 Department of Ophthalmology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

Received date: 2022-02-12

  Accepted date: 2022-07-08

  Online published: 2023-05-17

Supported by

National Natural Science Foundation of China: Effects of "Qingmang Yihao recipe" on retinal Ganglion Cells after Experimental Optic Nerve Injury(81874491);Exploring the Protective Mechanism of Astragaloside Ⅳ on Retinal Ganglion Cells after Trauma based on Autophagy Mediated by AMPK-mTOR-ULK1/2 signaling pathway(81973909)

Fold

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of Xuebijing injection (XBJ) on coronavirus disease 2019 (COVID-19) in patients.

METHODS: Related studies on multiple biological databases and websites were searched up to December 11, 2021 without language and publication time restrictions. Review Manager V.5.3 and Stata 14 software were used for data analysis.

RESULTS: Seven studies were finally included. The Meta-analysis showed that compared with the routine treatment alone, XBJ combined with the routine treatment can reduce the 28-day mortality (OR = 0.3, 95% CI: 0.12, 0.74), C-reactive protein (MD = —12.8, 95% CI: —23.13, —3.46), erythrocyte sedimentation rate (MD = —9.32, 95% CI: —14.66, —3.98) and interleukin-6 (SMD = —0.6, 95% CI: —1.04, —0.17) levels and increase the leukocyte (MD = 0.73, 95% CI: 0.42, 1.04) and lymphocyte count (MD = 0.18, 95% CI: 0.07, 0.29) in peripheral blood; additionally, it has no obvious side effects (OR = 1.11, 95% CI: 0.65, 1.9). There was no evidence that the XBJ combined therapy can improve the nucleic acid conversion rate and computed tomography improvement rate of COVID-19 patients.

CONCLUSIONS: Preliminary evidence suggests that XBJ combined with routine treatment seems to be more effective than routine treatment for patients with COVID-19. Limited by the number and quality of included papers, this finding still needs further validation by more studies.

Key words： COVID-19; Xuebijing injection; safety; treatment outcome; Meta-analysis, systematic review

Cite this article

Wu SUN , Yuwei ZHAO , Liang LIAO , Zhonghui ZHAO , Shiqi CHEN , Xiaoling YAN , Xueyao WANG , Guojun CHAO , Jian ZHOU . Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023 , 43(4) : 631 -639 . DOI: 10.19852/j.cnki.jtcm.20230517.002

References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-42.
2. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect 2020; 80: e14-7.
3. WHO Coronavirus (COVID-19) Dashboard, 2021-11-22, cited 2021-11-22. Available from URL: https://covid19.who.int/.
4. Xu X, Ong YK, Wang Y. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Mil Med Res 2020; 7: 22.
5. Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a Meta-analysis of randomized controlled trials. J Ethnopharmacol 2018; 224: 512-21.
6. Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med 2019; 47: e735-43.
7. National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of COVID-19 (5th Edition), 2020-02-04, cited 2021-11-22. Available from URL: www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf.
8. Ma Q, Qiu M, Zhou H, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res 2020; 160: 105073.
9. Zheng WJ, Yan Q, Ni YS, et al. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology. Bio Data Min 2020; 13: 17.
10. Zheng Y, Liu ZQ, Zhu XQ, Wang BL. To investigation of the mechanism of Xuebijing injection in COVID-19 treatment based on network pharmacology and molecular docking. Zhong Guo Bi Jiao Yi Xue Za Zhi 2020; 30: 57-64.
11. Li S, Lu W, Zhao XQ, et al. Therapeutic effect observation on different doses of Xuebijing injection in treatment of severe Corona Virus Disease 2019. Zhong Guo Zhong Xi Yi Jie He Ji Jiu Za Zhi 2020; 27: 267-70.
12. Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med 2021; 42: 101305.
13. Wen L, Zhou Z, Jiang D, Huang K. Effect of Xuebijing injection on inflammatory markers and disease outcome of Coronavirus Disease 2019. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2020; 32: 426-9.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
15. Higgins JP, Altman DG, G?tzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
16. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network Meta-analysis. Lancet 2019; 394: 939-51.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
18. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without Meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020; 368: l6890.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
20. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
21. Chen L, Liu H, Xiao G. The curative effect of Xuebijing injection in the treatment of new coronary pneumonia and its influence on CRP. Zhong Guo Chu Fang Yao 2020; 18: 110-1.
22. Guo H, Zheng J, Huang G, et al. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. Ann Palliat Med 2020; 9: 3235-48.
23. Liu K, Fu M, Zhang ZP, Zhang Z. The clinical efficacy of Xuebijing on patients with 2019 coronary pneumonia. Compilation of National Scientific Research Theory and Academic Research Achievements (IV), 2020-04-08, Beijing, China. Beijing: China Global Culture Press, 2020: 395-38.
24. Zhang C, Li Z, Zhang S, Wang W, Jiang X. Clinical observation of Xuebijing in the treatment of COVID-19. Zhong Guo Yi Yuan Yao Xue Za Zhi 2020; 40: 964-7.
25. Liu X, Song Y, Guan W, et al. A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2021; 33: 774-8.
26. Jiang M, Zhou M, Han Y, et al. Identification of NF-κB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. J Ethnopharmacol 2013; 147: 426-33.
27. Liu Y, Tian X, Cui M, Zhao S. Safflower yellow inhibits angiotensin Ⅱ-induced adventitial fibroblast proliferation and migration. J Pharmacol Sci 2014; 126: 107-14.
28. Wang Q, Wu X, Tong X, Zhang Z, Xu B, Zhou W. Xuebijing ameliorates sepsis-induced lung injury by downregulating HMGB1 and RAGE expressions in mice. Evid Based Complement Alternat Med 2015; 2015: 860259.
29. Wang Q, Mei J, Wang C, et al. Meta analysis on the treatment of coronavirus disease 2019 by Traditional Chinese and Western Medicine. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2021; 33: 714-20.
30. Shao M, Liu B, Wang JQ, et al. Effect of Xuebijing injection on T helper 17 and CD4+ CD25+ regulatory T cells in patients with sepsis. Zhong Guo Wei Zhong Bing Ji Jiu Yi Xue 2011; 23: 430-4.
31. Yao RQ, Ren C, Wang LX, Dong N, Wu Y, Yao YM. Influence of Xuebijing injection and its component paeoniflorin on immune function and survival rate of septic rats. Zhong Hua Shao Shang Za Zhi 2020; 36: 658-64.
32. Wang YB, Wang Q, Yao YM, Sheng ZY, Liu YF. Effect of Xuebijing injection on systemic lupus erythematosus in mice. Chin J Integr Med 2013; 19: 675-82.
33. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a Meta-analysis. Cytometry A 2020; 97: 772-6.
34. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun 2021; 538: 211-7.
35. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res 2020; 69: 379-88.
Options
Outlines

/

〈 〉